© 2021 Palmetto GBA, LLC
We frequently update our articles to reflect the latest changes and updates to Medicare, and strongly recommend you visit this article at link below to confirm you have the latest version.
Printed Date: 9/22/2015
Erythropoetic stimulating agent (ESA) administered to treat anemia due to anti-cancer radiotherapy.
HCPCS Procedure Codes
CMS MLN Matters article MM5699 (PDF, 74 KB): Reporting of Hematocrit or Hemoglobin Levels on All Claims for the Administration of Erythropoiesis Stimulating Agents (ESAs), Implementation of New Modifiers for Non-ESRD ESA Indications, and Reporting of Hematocrit or Hemoglobin Levels on all Non-ESRD, Non-ESA Claims Requesting Payment for Anti-Anemia Drugs
CMS transmittal 1413, Change Request 5818 (PDF, 209 KB)
CMS National Coverage Determination 110.21 - for Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions
CMS Medicare Claims Processing Manual (Pub. 100-04), Chapter 17, Section 80.8-80.12 (PDF, 492 KB)
CMS Medicare Benefit Policy Manual (Pub. 100.02), Chapter, Section 50
We value your opinion and want to provide the highest-quality and most relevant Medicare knowledge possible. Please let us know if this article was helpful.
It didn't answer my question
This article was helpful
We’re glad we could help you today and appreciate your feedback. When you rate our articles as most helpful, we know that we are on the right track for providing you with important news and information.
We're sorry this article didn't help you today. We'll use your feedback to review this article to try to revise or expand it. Contact us with more feedback or a question on this topic.
Last Updated: 07/16/2020